CryoLife Reports First Quarter 2019 Financial Results
ATLANTA, April 30, 2019 /PRNewswire/ --
First Quarter and Recent Business Highlights:
-- Total revenues were $67.5 million in the first quarter of 2019,
reflecting year over year growth of 9% and an 11% increase on a non-GAAP
constant currency basis, both compared to the first quarter of 2018
-- On-X(®) revenues increased 14%, and 15% on a non-GAAP constant
currency basis, both compared to the first quarter of 2018
-- JOTEC(®) revenues increased 10%, and 18% on a non-GAAP constant
currency basis, both compared to the first quarter of 2018
-- Net loss was ($297,000), or ($0.01) per fully diluted common share;
non-GAAP net income was $1.5 million, or $0.04 per fully diluted common
share
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the first quarter ended March 31, 2019.
"We had a successful start to the year posting solid financial results and advancing our clinical and R&D programs. Our strategy of differentiated products focused on select markets, supported by a well-trained direct sales force, is allowing us to continue to take market share," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Given our strong performance in the first quarter and the expected launch of the initial phase of our next generation products, we remain on track to deliver high single-digit top line growth in 2019. Our pipeline programs have increased our addressable market opportunity to $3.5 billion, positioning the Company for substantial growth in the coming years."
First Quarter 2019 Financial Results
Total revenues for the first quarter of 2019 were $67.5 million, reflecting growth of 9%, and 11% on a non-GAAP constant currency basis, both compared to the first quarter of 2018. The increase was driven by strong revenue growth from JOTEC, On-X, and BioGlue.
Net loss for the first quarter of 2019 was ($297,000), or ($0.01) per fully diluted common share, compared to a net loss of ($3.9) million, or ($0.11) per fully diluted common share for the first quarter of 2018. Non-GAAP net income for the first quarter of 2019 was $1.5 million, or $0.04 per fully diluted common share, compared to non-GAAP net income of $793,000, or $0.02 per fully diluted common share for the first quarter of 2018.
2019 Financial Outlook
CryoLife is reiterating its full-year financial guidance, with total revenues for 2019 expected to be in the range of $280 million to $284 million and non-GAAP earnings per share expected to be between $0.28 and $0.32.
All numbers are presented on a GAAP basis except where expressly referenced as non-GAAP. The Company does not provide GAAP income per common share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.
The Company's financial guidance for 2019 is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP results exclude (as applicable) business development and integration expenses, amortization expense, and inventory basis step-up expense. The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, and the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company does, however, expect to incur similar types of expenses in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, April 30, 2019 at 4:30 p.m. EDT to discuss the results followed by a question and answer session. To listen to the live teleconference, please dial 201-689-8261. A replay of the teleconference will be available through May 7, 2019 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The Conference ID for the replay is 13690095.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our belief that our strategy of differentiated products focused on select markets, supported by a well-trained direct sales force, is allowing us to continue to take market share; the timing of our expected launch of the initial phase of our next generation products; our belief that we remain on track to deliver high single-digit top line growth in 2019; our belief that our addressable market opportunity is $3.5 billion; and our belief that we are positioned for substantial growth in the coming years. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2018. CryoLife does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
CRYOLIFE, INC. AND SUBSIDIARIES
Financial Highlights
(In thousands, except per share data)
(Unaudited)
Three Months Ended
March 31,
2019 2018
Revenues:
Products $
48,401 $
43,598
Preservation services 19,104 18,350
Total revenues 67,505 61,948
Cost of products and preservation
services:
Products 13,826 14,157
Preservation services 9,406 8,563
Total cost of products and preservation
services 23,232 22,720
Gross margin 44,273 39,228
Operating expenses:
General, administrative, and marketing 36,520 37,348
Research and development 5,548 5,370
Total operating expenses 42,068 42,718
2,205 (3,490)
Operating income (loss)
Interest expense 3,894 3,656
Interest income (116) (59)
Other expense (income), net 77 (181)
(1,650) (6,906)
Loss before income taxes
Income tax benefit (1,353) (3,051)
Net loss $
(297) $
(3,855)
Loss per common share:
Basic $
(0.01) $
(0.11)
Diluted $
(0.01) $
(0.11)
Weighted-average common shares
outstanding:
Basic 36,778 36,146
Diluted 36,778 36,146
CRYOLIFE, INC. AND SUBSIDIARIES
Fina
ncial Highlights
(In thousands)
(Unaudited)
Three Months Ended
March 31,
2019 2018
Products:
BioGlue $
17,222 $
15,970
JOTEC 15,954 14,460
On-X 11,731 10,309
CardioGenesis cardiac laser therapy 1,714 1,346
PerClot 1,050 972
PhotoFix 730 541
Total Products 48,401 43,598
Preservation services:
Cardiac tissue 8,930 8,103
Vascular tissue 10,174 10,247
Total preservation services 19,104 18,350
Total revenues $
67,505 $
61,948
Revenues:
U.S. $
37,325 $
34,888
International 30,180 27,060
Total revenues $
67,505 $
61,948
(Unaudited)
March 31, December 31,
2019 2018
Cash, cash equivalents,
and restricted securities $
41,075 $
42,236
Total current assets 178,652 179,168
Total assets 586,928 571,091
Total current liabilities 36,423 34,523
Total liabilities 314,306 296,024
Shareholders' equity 272,622 275,067
CRYOLIFE, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP
Net (Loss) Income and Diluted (Loss) Income Per Common Share
(In thousands, except per share data)
(Unaudited)
Three Months Ended
March 31,
2019 2018
GAAP:
Loss before income taxes $
(1,650) $
(6,906)
Income tax benefit (1,353) (3,051)
Net loss $
(297) $
(3,855)
Diluted loss per common share: $
(0.01) $
(0.11)
Reconciliation of income before
income taxes,
GAAP to adjusted net income,
non-GAAP:
Loss before income taxes, GAAP $
(1,650) $
(6,906)
Adjustments:
Business development and
integration expenses 1,109 3,722
Amortization expense 2,579 2,735
Inventory basis step-up expense 1,506
Adjusted income before income
taxes,
non-GAAP 2,038 1,057
Income tax expense calculated at
a
pro forma tax rate of 25% 510 264
Adjusted net income, non-GAAP $
1,528 $
793
Reconciliation of diluted (loss)
income per common
share, GAAP to adjusted diluted
(loss) income per
common share, non-GAAP:
Diluted loss per common share -
GAAP $
(0.01) $
(0.11)
Adjustments:
Business development and
integration expenses 0.03 0.10
Amortization expense 0.07 0.07
Inventory basis step-up expense 0.04
Tax effect of non-GAAP
adjustments (0.03) (0.05)
Effect of 25% pro forma tax rate (0.02) (0.03)
Adjusted diluted income per
common share,
non-GAAP: $
0.04 $
0.02
Diluted weighted-average common
shares outstanding: 37,711 36,985
CRYOLIFE, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP
Revenues; Gross Margin; General, Administrative, and Marketing
Adjusted EBITDA
(In thousands, except per share data)
(Unaudited)
Three Months Ended
March 31,
2019 2018 Growth Rate
Reconciliation of total revenues, GAAP to
total revenues, non-GAAP:
Total revenues, GAAP $
67,505 $
61,948 9%
Impact of changes in currency exchange (1,337)
Total constant currency revenues, non-GAAP $
67,505 $
60,611 11%
Reconciliation of total JOTEC revenues, GAAP to
total JOTEC revenues, non-GAAP:
Total JOTEC revenues, GAAP $
15,954 $
14,460 10%
Impact of changes in currency exchange (986)
Total constant currency JOTEC revenues, non-GAAP $
15,954 $
13,474 18%
Reconciliation of total On-X revenues, GAAP to
total On-X revenues, non-GAAP:
Total On-X revenues, GAAP $
11,731 $
10,309 14%
Impact of changes in currency exchange (77)
Total constant currency On-X revenues, non-GAAP $
11,731 $
10,232 15%
(Unaudited)
Three Months Ended
March 31,
2019 2018
Reconciliation of net (loss) income, GAAP
to adjusted EBITDA, non-GAAP:
Net (loss) income, GAAP $
(297) $
(3,855)
Adjustments:
Depreciation and amortization expense 4,350 4,376
Income tax benefit (1,353) (3,051)
Interest income (116) (59)
Interest expense 3,894 3,656
Inventory basis step-up expense 1,506
Business development and integration expenses 1,109 3,722
Loss (gain) on foreign currency revaluation 74 (32)
Stock-based compensation expense 1,853 1,248
Adjusted EBITDA, non-GAAP $
9,514 $
7,511
CryoLife
Gilmartin Group LLC
D. Ashley Lee
Greg Chodaczek / Lynn Lewis
Executive Vice President, Chief Financial
Officer
Phone: 646-924-1769
and Chief Operating Officer
Phone: 770-419-3355
investors@cryolife.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cryolife-reports-first-quarter-2019-financial-results-300840863.html
SOURCE CryoLife, Inc.
